Results 191 to 200 of about 5,563 (240)

Author Correction: Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells. [PDF]

Sci Rep
Wathikthinnakon M, Luangwattananun P, Sawasdee N, Chiawpanit C, Lee VS, Nimmanpipug P, Tragoolpua Y, Rotarayanont S, Sangsuwannukul T, Phanthaphol N, Wutti-In Y, Somboonpatarakun C, Chieochansin T, Junking M, Sujjitjoon J, Yenchitsomanus PT, Panya A.   +16 more
europepmc   +1 more source

Targeted desialylation and cytolysis of tumour cells by fusing a sialidase to a bispecific T-cell engager. [PDF]

Nat Biomed Eng
Yang Z, Hou Y, Grande G, Cho JH, Wang C, Shi Y, Zak J, Wan Y, Qin K, Liu D, Teijaro JR, Lerner RA, Wu P.   +12 more
europepmc   +1 more source

Correspondence on 'Cardiovascular toxicities associated with bispecific T-cell engager therapy' by Sayed <i>et al</i>. [PDF]

J Immunother Cancer
Noguchi Y, Yan M, Tachi T, Yoshimura T.
europepmc   +1 more source

Response to: Correspondence on 'Cardiovascular toxicities associated with bispecific T-cell engager therapy' by Noguchi <i>et al</i>. [PDF]

J Immunother Cancer
Sayed A, Munir M, Poliner M, Sughra S, Epperla N, Addison D.   +5 more
europepmc   +1 more source

Targeting of acute myeloid leukemia by five-gene engineered T cells expressing transgenic T-cell receptor specific to WT1, chimeric antigenic receptor specific to GM-CSF receptor, bispecific T-cell engager specific to CD33, and tEGFR suicide gene system. [PDF]

Immunother Adv
Šmilauerová K, Štach M, Mucha M, Vaníková Š, Rychlá J, Otáhal P.   +5 more
europepmc   +1 more source

[The Chinese clinical expert consensus for the BCMA bispecific T cell engager in the treatment of multiple myeloma (2025)]. [PDF]

Zhonghua Xue Ye Xue Za Zhi
Chinese Hematology Association, Chinese Myeloma Committee, Plasma Cell Disease Group, Chinese Society of Hematology, Chinese Medical Association, Chinese Geriatrics Association, Society of Hematology.   +6 more
europepmc   +1 more source

Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells. [PDF]

J Immunother Cancer
Baugh R, Khalique H, Page E, Lei-Rossmann J, Wan PK, Johanssen T, Ebner D, Ansorge O, Seymour LW.   +8 more
europepmc   +1 more source

Immune-related adverse events with bispecific T-cell engager therapy targeting B-cell maturation antigen. [PDF]

Haematologica
Piron B, Bastien M, Antier C, Dalla-Torre R, Jamet B, Gastinne T, Dubruille V, Moreau P, Martin J, Bénichou A, Touzeau C, Tessoulin B.   +11 more
europepmc   +1 more source